Emedgene, Illumina partner on rare disease analysis

By The Science Advisory Board staff writers

December 16, 2020 -- Emedgene and Illumina have partnered to interpret genomic data for rare diseases.

Features from Emedgene's artificial intelligence (AI) powered Cognitive Genomics Intelligence were integrated into Illumina's TruSight software. TruSight enables sample-to-report analysis for genetic disease testing, allowing researchers to go from millions of variants to a small number in a rapid, scalable way. Together, they expect researchers will make new and unexpected discoveries, according to the companies.


Copyright © 2020 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here